SCHEMBL5202983

SCHEMBL5202983

CS(=O)(=O)Nc1cc(N)ccc1Cl

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 1/20 0.47
PIK3CA P42336 1/20 0.47
PIK3CB P42338 1/20 0.47
PIK3CG P48736 1/20 0.47
DRD2 P14416 2/20 0.44
DRD3 P35462 2/20 0.44
CYP3A4 P08684 3/20 0.43
TSHR P16473 2/20 0.43
ALDH1A1 P00352 3/20 0.43
HSD17B10 Q99714 2/20 0.43
HPGD P15428 2/20 0.43
THRB P10828 1/20 0.43
ALOX15 P16050 1/20 0.43
CASP1 P29466 1/20 0.43
RECQL P46063 1/20 0.43
MCL1 Q07820 2/20 0.42
BACE1 P56817 1/20 0.42
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
MAPT P10636 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6816106 0.87 CYP3A4 (0.48) PIK3CDPIK3CAPIK3CBPIK3CGCYP3A4
SCHEMBL3244812 0.82 L3MBTL1 (0.42) PIK3CDPIK3CAPIK3CBPIK3CGALDH1A1
SCHEMBL17507358 0.82 PSIP1 (0.42) CYP3A4TSHRALDH1A1HSD17B10HPGD
SCHEMBL11572085 0.81 HSD17B10 (0.52) CYP3A4TSHRALDH1A1HSD17B10HPGD
SCHEMBL19099945 0.81 GAA (0.41) PIK3CDPIK3CAPIK3CBPIK3CGALDH1A1
SCHEMBL8697280 0.81 ALDH1A1 (0.46) PIK3CACYP3A4TSHRALDH1A1HSD17B10
SCHEMBL17526252 0.81 MCL1 (0.42) CYP3A4TSHRALDH1A1HSD17B10HPGD
SCHEMBL18739949 0.80 MAPT (0.46) PIK3CACYP3A4TSHRALDH1A1HSD17B10
SCHEMBL8186657 0.79 PIK3CD (0.45) PIK3CDPIK3CAPIK3CBPIK3CGDRD2
SCHEMBL3790081 0.79 BACE1 (0.52) DRD2DRD3ALDH1A1HPGDMCL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3617213-B1 THIENO[3,2-D]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES HANMI PHARMACEUTICAL CO LTD (KR) 2025-02-19 EP disclosed
EP-3617213-A1 THIENO[3,2-D]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES Hanmi Pharm. Co., Ltd. (KR) 2020-03-04 EP disclosed
EP-2797927-B1 THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES HANMI PHARM IND CO LTD (KR) 2019-09-25 EP disclosed
US-RE47451-E1 Thieno[3,2-D]pyrimidine derivatives having inhibitory activity for protein kinases HANMI PHARM. CO. LTD. (KR) 2019-06-25 US disclosed
US-9156852-B2 Thieno[3,2-D]pyrimidine derivatives having inhibitory activity for protein kinases HANMI PHARM. CO., LTD (KR) 2015-10-13 US disclosed
US-20140371219-A1 THIENO[3,2-D]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES HANMI PHARM. CO., LTD (KR) 2014-12-18 US disclosed
EP-2797927-A1 THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES Hanmi Pharm. Co., Ltd. (KR) 2014-11-05 EP disclosed
WO-2013100632-A1 THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES HANMI PHARM CO., LTD. (KR) 2013-07-04 WO disclosed
EP-0887346-B1 N-Phenyl-alkylsulfonamide derivatives, their preparation and their use as alpha1A/1L adrenoceptor agonists HOFFMANN LA ROCHE (CH) 2007-12-12 EP disclosed
US-6057349-A ALPHA.SUB.1A/1L AGONISTS USED IN THE TREATMENT OF VARIOUS DISEASE STATES SUCH AS URINARY INCONTINENCE, NASAL CONGESTION, PRIAPISM, DEPRESSION, ANXIETY, DEMENTIA, SENILITY, ALZHEIMER'S, DEFICIENCIES IN ATTENTIVENESS AND COGNITION, AND F. HOFFMAN LA ROCHE AG (CH) 2000-05-02 US disclosed
US-5952362-A INHIBITOR OF GLYCOGEN PHOSPHORYLASE ENZYMETIC ACTIVITY AND GLUCOSE ACITIVITY SYNTEX (U.S.A) INC. (US) 1999-09-14 US disclosed
EP-0887346-A2 Phenyl-and aminophenyl-alkylsulfonamide and urea derivatives, their preparation and their use as alpha1A/1L adrenoceptor agonists F. HOFFMANN-LA ROCHE AG (CH) 1998-12-30 EP disclosed
EP-0490936-B1 PRODUCTION OF TRIAZOLINONES FMC CORP (US) 1996-10-23 EP disclosed
EP-0490936-A4 PRODUCTION OF TRIAZOLINONES 1992-10-14 EP disclosed
EP-0490936-A1 PRODUCTION OF TRIAZOLINONES. FMC CORP (US) 1992-06-24 EP disclosed
WO-1991003470-A1 PRODUCTION OF TRIAZOLINONES FMC CORPORATION (US) 1991-03-21 WO disclosed
US-4980480-A Production of triazolinones FMC CORPORATION (US) 1990-12-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140371219-A1 THIENO[3,2-D]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES TK1, DTYMK, MAP4K2 PIK3CD 106/4885PIK3CA 143/4885PIK3CB 123/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.